A Phase 1/2 Trial of ADI-270 in CcRCC
This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Clear Cell Renal Cell Carcinoma
DRUG: ADI-270|DRUG: Fludarabine|DRUG: Cyclophosphamide
The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort, This primary endpoint will be used to determine the Maximum Tolerated Dose (MTD) or Maximum Assessed dose (MAD), Day 28|Proportion of treatment emergent and treatment related adverse events, This primary endpoint will be used to determine the MTD/MAD of ADI-270, 2 years
This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.